140 related articles for article (PubMed ID: 21755401)
41. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.
Cotté FE; Fardellone P; Mercier F; Gaudin AF; Roux C
Osteoporos Int; 2010 Jan; 21(1):145-55. PubMed ID: 19459025
[TBL] [Abstract][Full Text] [Related]
42. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
García-Hernández P; Carranza-Lira S; Motta-Martínez E
Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
[TBL] [Abstract][Full Text] [Related]
43. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
44. Adherence to bisphosphonate therapy in postmenopausal osteoporotic women.
Kuzmanova SI; Solakov PC; Geneva-Popova MG
Folia Med (Plovdiv); 2011; 53(3):25-31. PubMed ID: 22359979
[TBL] [Abstract][Full Text] [Related]
45. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
Borek DM; Smith RC; Gruber CN; Gruber BL
Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
[TBL] [Abstract][Full Text] [Related]
46. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
47. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization.
Sunyecz JA; Mucha L; Baser O; Barr CE; Amonkar MM
Osteoporos Int; 2008 Oct; 19(10):1421-9. PubMed ID: 18351427
[TBL] [Abstract][Full Text] [Related]
48. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
49. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice.
Weycker D; Lamerato L; Schooley S; Macarios D; Siu Woodworth T; Yurgin N; Oster G
Osteoporos Int; 2013 Apr; 24(4):1483-9. PubMed ID: 22903292
[TBL] [Abstract][Full Text] [Related]
50. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.
Fardellone P; Lello S; Cano A; de Sá Moreira E; Watanabe de Oliveira R; Julian GS; Tang B
Clin Ther; 2019 Aug; 41(8):1576-1588. PubMed ID: 31151814
[TBL] [Abstract][Full Text] [Related]
51. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
52. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database.
Abrahamsen B
Osteoporos Int; 2013 Jan; 24(1):369-72. PubMed ID: 22572963
[TBL] [Abstract][Full Text] [Related]
53. Low persistence with oral biphosphonate treatment in postmenopausal osteoporosis.
Torre C; Guerreiro J; Mendes Z; Miranda A; Bragança F; Cristino J; Canhão H; Branco JC
Acta Reumatol Port; 2019; 44(2):114-125. PubMed ID: 31280276
[TBL] [Abstract][Full Text] [Related]
54. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink.
Morley J; Moayyeri A; Ali L; Taylor A; Feudjo-Tepie M; Hamilton L; Bayly J
Osteoporos Int; 2020 Mar; 31(3):533-545. PubMed ID: 31758206
[TBL] [Abstract][Full Text] [Related]
55. Compliance, Persistence, and Preferences Regarding Osteoporosis Treatment During Active Therapy or Drug Holiday.
Eliasaf A; Amitai A; Maram Edry M; Yosselson Superstine S; Rotman Pikielny P
J Clin Pharmacol; 2016 Nov; 56(11):1416-1422. PubMed ID: 26999526
[TBL] [Abstract][Full Text] [Related]
56. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
Bonnick S; De Villiers T; Odio A; Palacios S; Chapurlat R; DaSilva C; Scott BB; Le Bailly De Tilleghem C; Leung AT; Gurner D
J Clin Endocrinol Metab; 2013 Dec; 98(12):4727-35. PubMed ID: 24064689
[TBL] [Abstract][Full Text] [Related]
57. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
[TBL] [Abstract][Full Text] [Related]
58. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
59. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review.
Fatoye F; Smith P; Gebrye T; Yeowell G
BMJ Open; 2019 Apr; 9(4):e027049. PubMed ID: 30987990
[TBL] [Abstract][Full Text] [Related]
60. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
